Navigation Links
Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma
Date:12/8/2008

PRINCETON, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today results from a preclinical study for MDX-1401, a second-generation non-fucosylated version of MDX-060 that targets CD30, a marker for activated lymphocytes that is present on the malignant cells of Hodgkin's lymphoma (HL) as well as other CD30-expressing cancers. MDX-1401 demonstrated almost a doubling in potency and efficacy in cell lines when compared to MDX-060. The improved potency and efficacy of MDX-1401 in in vivo xenograft models indicates enhanced antibody-dependent cellular cytotoxicity (ADCC) activity, an important mechanism of action of therapeutic antibodies. In addition to anti-tumor activity, the preclinical data showed a statistically significant increase in median survival time for the MDX-1401 treatment group when compared to the MDX-060 treatment group.

The data were presented in a poster presentation entitled "Characterization of MDX-1401, a human anti-CD30 antibody with enhanced effector function, for therapy of malignant lymphoma" (abstract #1580) at the 50th Annual Meeting of the American Society of Hematology (ASH) being held December 6-9, 2008 in San Francisco, CA.

"We are excited with the growing body of scientific evidence that indicates enhanced ADCC and improved anti-tumor efficacy with the second generation anti-CD30 antibody, MDX-1401, as compared to MDX-060," said Geoffrey M. Nichol, MBChB, Senior Vice President of Product Development at Medarex. "The data we have seen to date continues to inform our development plans and underscores the importance of assessing MDX-1401 as a potentially more potent therapeutic for CD-30 expressing malignancies. We look forward to presenting results from the ongoing Phase 1 MDX-1401 study and the recently completed Phase 2 MDX-060 study in 2009."

More information about the ASH Annual Meeting may be found at www.hematology.org

About MDX-1401

MDX-1401 is a non-fucosylated version of the MDX-060 antibody and is enhanced for greater antibody-dependent cellular cytotoxicity (ADCC) activity, an important function of the human immune system, whereby immune cells can kill target cells. ADCC activity is one important mechanism underlying the efficacy of some currently approved anti-cancer antibodies. A dose-escalation, multi-dose Phase 1 clinical trial of MDX-1401 in up to 36 patients with relapsed or refractory Hodgkin's lymphoma (HL) is currently ongoing, with results expected in 2009. The trial is designed to establish and evaluate the safety profile and initial efficacy of the antibody.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, the statements relating to MDX-1401 in this press release may constitute forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development of MDX-1401, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
2. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
3. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
4. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
5. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
6. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
9. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
10. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
11. Medarex Announces Ipilimumab Program Continues to Move Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , Connecticut’s ... Awards (EIA), held this past Thursday night at The Space in Hamden. ... their innovative project ideas to a panel of judges for an opportunity to ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... rallying cry to Americans to watch for the discomforts and hidden dangers of ... to senior citizens, everyone is at risk for developing fungal infections on the ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... unveiled the MirixaPro 6.0 platform. As the industry’s leading Medication Therapy Management ... delivered. Based on industry research and market feedback, the latest version of ...
(Date:9/19/2017)... Philadelphia, PA (PRWEB) , ... September 19, 2017 ... ... high-quality orthopedic dog beds, has been officially recognized for its September 2016 donation ... , The company recently received three awards and honors for its contribution ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
Breaking Medicine News(10 mins):